CSI Market
Sign In | Register

Opiant Pharmaceuticals Inc (OPNT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access OPNT quarterly Cash Flow →
The data below summarizes Opiant Pharmaceuticals Inc's cash flow activity from Dec 31 2017 to Dec 31 2021, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2021)
12 Months 		(Dec 31 2020) (Dec 31 2019) (Dec 31 2018) (Dec 31 2017)
Operating Activities
Income3.01
Depreciation & amortization0.09
Amortization of Other Assets0.27
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation2.75
Income (Loss) from Equity Method Investments0.00
Adjustment of Warrants Granted for Services0.00
Issuance Of Stock As Deferred Financing Cost-
Issuance Of Stock And Warrants For Financing Costs-
Stock Based Compensation From Issuance Of Warrants-
Gain Loss Related To Litigation Settlement-
Increase Decreasein Contract with Customer Liability-
Operating Lease Right Of Use Asset Amortization0.57
Increase Decrease In Contract With Customer Liability-0.34
Operating Lease Expense-
Increase Decreasein License Fee Payable-
Operating Lease Expense Non Cash-0.57
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-5.01
Accounts Payable1.32
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.16
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities1.93
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities-15.01
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Investment Projects0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-15.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.72
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Return Of Profit-
Proceeds From Stock Options And Warrants Exercised-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.72
Effect of exchange rate on cash flow-0.03
Discontinued operations0.00
Free Cash Flow1.93
Total Cash Flow-10.40
4 historic quarters locked

Sign in to unlock the full Opiant Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Opiant Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001385508-22-000131

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License